DexCom, Inc. (DXCM)
NASDAQ: DXCM · IEX Real-Time Price · USD
125.88
-1.51 (-1.19%)
At close: May 1, 2024, 4:00 PM
126.29
+0.41 (0.33%)
Pre-market: May 2, 2024, 4:15 AM EDT

DexCom Revenue

DexCom had revenue of $3.80B in the twelve months ending March 31, 2024, with 25.78% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $921.00M with 24.21% year-over-year growth. In the year 2023, DexCom had annual revenue of $3.62B with 24.49% growth.

Revenue (ttm)
$3.80B
Revenue Growth
+25.78%
P/S Ratio
13.17
Revenue / Employee
$396,021
Employees
9,600
Market Cap
50.06B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20233.62B712.50M24.49%
Dec 31, 20222.91B461.30M18.84%
Dec 31, 20212.45B521.80M27.08%
Dec 31, 20201.93B450.70M30.54%
Dec 31, 20191.48B444.40M43.08%
Dec 31, 20181.03B313.10M43.58%
Dec 31, 2017718.50M145.20M25.33%
Dec 31, 2016573.30M171.30M42.61%
Dec 31, 2015402.00M142.80M55.09%
Dec 31, 2014259.20M99.20M62.00%
Dec 31, 2013160.00M60.10M60.16%
Dec 31, 201299.90M23.60M30.93%
Dec 31, 201176.30M27.70M57.00%
Dec 31, 201048.60M18.91M63.67%
Dec 31, 200929.69M19.86M201.82%
Dec 31, 20089.84M5.21M112.62%
Dec 31, 20074.63M2.46M113.23%
Dec 31, 20062.17M--
Dec 31, 20050--
Dec 31, 20040--
Dec 31, 20030--
Dec 31, 20020--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
McKesson 301.51B
Cencora 271.58B
Takeda Pharmaceutical 29.40B
Gilead Sciences 27.12B
Becton, Dickinson and Company 19.49B
IQVIA Holdings 14.98B
Zoetis 8.54B
Moderna 6.85B
Revenue Rankings